Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune Therapeutics plc (NASDAQ:ADAP) fell $3.21 (30%) to $7.55 on Monday after reporting that zero of 17 evaluable patients achieved a response across the first two dose cohorts of three Phase I trials evaluating the company's MAGE-A10 and MAGE-A4 SPEAR T cell therapies to treat various cancers. Data were presented at the European Society for Medical Oncology meeting in Munich.

Among 11 evaluable patients with non-small cell lung cancer (NSCLC), melanoma or head and neck cancer in two Phase I trials of MAGE-A10, eight patients had disease progression, one patient died of pneumonia unrelated to treatment, one patient had stable disease at week four but then progressed, and one patient had stable disease at weeks four and eight but progressed at week 12. Seven patients had serious adverse events, including two with cytokine release syndrome (CRS) and one with hemoptysis...